Genmab A/S
GE9.F
Frankfurt Stock Exchange243.90
EUR
-0.40
- -
Genmab A/S
GE9.F
(Frankfurt Stock Exchange)
Recent
price
243.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genmab A/S is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics primarily for the treatment of cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, Denmark, the company focuses on innovative antibody technology platforms, including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. Genmab's core products include Epkinly (epcoritamab) for relapsed/refractory diffuse large B-cell lymphoma, Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer, Darzalex (daratumumab) for multiple myeloma, Kesimpta (ofatumumab) for relapsing multiple sclerosis, and Tepezza (teprotumumab) for thyroid eye disease. These therapeutics are developed and marketed in collaboration with major pharmaceutical partners. Recent major developments include the strategic acquisition of Merus in 2025, a clinical-stage biotech company, broadening Genmab’s late-stage oncology pipeline with assets such as petosemtamab, a late-stage therapy in Phase 3 development with two FDA Breakthrough Therapy Designations for head and neck cancer. This acquisition reinforces Genmab’s commitment to expanding its proprietary pipeline and accelerating sustainable growth, with expectations of new product launches by 2027 and projected annual sales exceeding $1 billion by 2029. Genmab operates globally, leveraging strategic partnerships and continuous R&D investment driven by its proprietary antibody platforms such as DuoBody and HexaBody to innovate and commercialize next-generation antibody medicines. The company reported significant financial growth in 2024, underpinned by strong sales from Darzalex and other partnered products, positioning itself as a leading player in antibody therapeutics for cancer and autoimmune diseases. Genmab aims to transform cancer treatment and improve patient outcomes by 2030 through its proprietary, innovative antibody medicines.